结合新型类毒素与新型佐剂的艰难梭菌疫苗在兔中的免疫原性与安全性
本研究在兔中评估经金属催化氧化(MCO)灭活的艰难梭菌毒素TcdA和TcdB联合新型碳水化合物脂肪酸单硫酸酯(CMS)佐剂的免疫原性与安全性。两或三次肌内免疫可产生针对两种毒素的高滴度血清IgG和中和抗体,CMS佐剂增强对两种毒素的抗体应答而铝佐剂对照仅对TcdA有效。免疫后体重增长稳定,首次免疫后体温升高至多1˚C,CMS佐剂组白细胞计数及中性粒细胞百分比升高,注射部位组织病理学未见异常反应。
要点
- MCO灭活的TcdA和TcdB联合CMS佐剂在兔中诱导针对两种毒素的高滴度血清IgG和中和抗体。
- CMS佐剂增强对TcdA和TcdB的抗体应答,铝佐剂对照仅对TcdA有效。
- 免疫后体重增长稳定,首次免疫后体温升高至多1˚C,注射部位未见异常组织反应。
核心结论
- 经MCO灭活的TcdA和TcdB联合CMS佐剂在兔中显示有前景的免疫原性和安全性,可能成为针对艰难梭菌感染的候选疫苗。
研究设计与样本
- 在兔中研究经金属催化氧化(MCO)灭活的TcdA和TcdB联合新型碳水化合物脂肪酸单硫酸酯(CMS)佐剂的免疫原性与安全性,并设铝佐剂对照。
主要发现
- 两或三次肌内免疫产生针对TcdA和TcdB的高滴度血清IgG和中和抗体。
- CMS佐剂增强对两种毒素的抗体应答,而铝佐剂对照仅对TcdA有效。
- 所有组体重增长稳定,首次免疫后一天体温升高至多1˚C,第二或第三次免疫后升高较少。
- CMS佐剂疫苗免疫后一天白细胞计数和中性粒细胞百分比升高,铝佐剂组未见此变化。
- 末次注射后42天注射部位组织病理学未见异常组织反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clostridioides difficile infection (CDI) is a serious healthcare-associated disease, causing symptoms such as diarrhea and pseudomembranous colitis. The major virulence factors responsible for the disease symptoms are two secreted cytotoxic proteins, TcdA and TcdB. A parenteral vaccine based on formaldehyde-inactivated TcdA and TcdB supplemented with alum adjuvant, has previously been investigated in humans but resulted in an insufficient immune response. In search for an improved response, we investigated a novel toxin inactivation method and a novel, potent adjuvant. Inactivation of toxins by metal-catalyzed oxidation (MCO) was previously shown to preserve neutralizing epitopes and to annihilate reversion to toxicity. The immunogenicity and safety of TcdA and TcdB inactivated by MCO and combined with a novel carbohydrate fatty acid monosulphate ester-based (CMS) adjuvant were investigated in rabbits. Two or three intramuscular immunizations generated high serum IgG and neutralizing antibody titers against both toxins. The CMS adjuvant increased antibody responses to both toxins while an alum adjuvant control was effective only against TcdA. Systemic safety was evaluated by monitoring body weight, body temperature, and analysis of red and white blood cell counts shortly after immunization. Local safety was assessed by histopathologic examination of the injection site at the end of the study. Body weight gain was constant in all groups. Body temperature increased up to 1 ˚C one day after the first immunization but less after the second or third immunization. White blood cell counts, and percentage of neutrophils increased one day after immunization with CMS-adjuvanted vaccines, but not with alum. Histopathology of the injection sites 42 days after the last injection did not reveal any abnormal tissue reactions. From this study, we conclude that TcdA and TcdB inactivated by MCO and combined with CMS adjuvant demonstrated promising immunogenicity and safety in rabbits and could be a candidate for a vaccine against CDI.
引用
- Aminzadeh A, Hilgers L, Paul Platenburg P, et al. Immunogenicity and safety in rabbits of a Clostridioides difficile vaccine combining novel toxoids and a novel adjuvant. Vaccine. 2024. PMID: 38336558. doi:10.1016/j.vaccine.2024.01.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。